Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels

Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels

Highly promising preclinical data obtained in cultured cells and in nude mice bearing xenografts contrast with the rather modest clinical efficacy of Polo-like kinase 1 (Plk1) inhibitors. In the present study, we investigated if Plk1 might be a suitable target in hepatocellular carcinoma (HCC) and...

Full description

Bibliographic Details
Main Authors: Jörg Haupenthal, Verena Bihrer, Huedayi Korkusuz, Otto Kollmar, Christian Schmithals, Susanne Kriener, Knut Engels, Thomas Pleli, Alexander Benz, Marta Canamero, Thomas Longerich, Bernd Kronenberger, Swantje Richter, Oliver Waidmann, Thomas J. Vogl, Stefan Zeuzem, Albrecht Piiper
Format: Article
Language:English
Published: Elsevier 2012-05-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558612800169

Internet

http://www.sciencedirect.com/science/article/pii/S1476558612800169

Similar Items